Home › Multiple Myeloma › Kansas
Pag-aaral pangklinika para sa Multiple Myeloma sa Kansas
12 pag-aaral para sa Multiple Myeloma ang naghahanap ng mga kalahok sa mga site sa Kansas.
Mga Lungsod sa Kansas
Opisyal na teksto ng pag-aaral (English)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Kansas City
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT07391657A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- University of Kansas Cancer Center, Kansas City
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07258511A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Kansas University Medical Center, Westwood
Nagre-recruitPhase 4
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT05201781Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
- University of Kansas Cancer Center, Kansas City
- University of Kansas Cancer Center-Overland Park, Overland Park
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- at 1 pa
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06465316Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- The University of Kansas Cancer Center - Westwood, Westwood
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT06297226A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- University of Kansas, Westwood
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT06980480MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- American Oncology Partners, P.A. Dba MidAmerica Cancer Care, Kansas City
- Ascentist Doctors' Hospital, Leawood
- American Oncology Partners, P.A. Dba MidAmerica Cancer Care, Merriam
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 24, 2026 · NCT06152575Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Central Care Cancer Center - Garden City, Garden City
- Central Care Cancer Center - Great Bend, Great Bend
- Mercy Hospital Pittsburg, Pittsburg
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT04566328Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Wichita
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 14, 2026 · NCT07764978Integrated Cancer Repository for Cancer Research
- Saint Luke's Cancer Instititute - South, Overland Park
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 19 hanggang 110 · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT02012699Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Central Care Cancer Center - Garden City, Garden City
- Central Care Cancer Center - Great Bend, Great Bend
Nagre-recruitPhase 3
Lahat ng edad · Lahat ng kasarian · Na-update Hun 10, 2026 · NCT05561387Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- University of Kansas Clinical Research Center, Westwood
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update May 19, 2026 · NCT06433947Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.